HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deficiency of T-type Ca2+ channels Cav3.1 and Cav3.2 has no effect on angiotensin II-induced hypertension but differential effect on plasma aldosterone in mice.

Abstract
T-type Ca2+ channel Cav3.1 promotes microvessel contraction ex vivo. It was hypothesized that in vivo, functional deletion of Cav3.1, but not Cav3.2, protects mice against angiotensin II (ANG II)-induced hypertension. Mean arterial blood pressure (MAP) and heart rate were measured continuously with chronically indwelling catheters during infusion of ANG II (30 ng·kg-1·min-1, 7 days) in wild-type (WT), Cav3.1-/-, and Cav3.2-/- mice. Plasma aldosterone and renin concentrations were measured by radioimmunoassays. In a separate series, WT mice were infused with ANG II (100 ng·kg-1·min-1) with and without the mineralocorticoid receptor blocker canrenoate. Cav3.1-/- and Cav3.2-/- mice exhibited no baseline difference in MAP compared with WT mice, but day-night variation was blunted in both Cav3.1 and Cav3.2-/- mice. ANG II increased significantly MAP in WT, Cav3.1-/-, and Cav3.2-/- mice with no differences between genotypes. Heart rate was significantly lower in Cav3.1-/- and Cav3.2-/- mice compared with control mice. After ANG II infusion, plasma aldosterone concentration was significantly lower in Cav3.1-/- compared with Cav3.2-/- mice. In response to ANG II, fibrosis was observed in heart sections from both WT and Cav3.1-/- mice and while cardiac atrial natriuretic peptide mRNA was similar, the brain natriuretic peptide mRNA increase was mitigated in Cav3.1-/- mice ANG II at 100 ng/kg yielded elevated pressure and an increased heart weight-to-body weight ratio in WT mice. Cardiac hypertrophy, but not hypertension, was prevented by the mineralocorticoid receptor blocker canrenoate. In conclusion, T-type channels Cav3.1and Cav3.2 do not contribute to baseline blood pressure levels and ANG II-induced hypertension. Cav3.1, but not Cav3.2, contributes to aldosterone secretion. Aldosterone promotes cardiac hypertrophy during hypertension.
AuthorsAnne D Thuesen, Stine H Finsen, Louise L Rasmussen, Ditte C Andersen, Boye L Jensen, Pernille B L Hansen
JournalAmerican journal of physiology. Renal physiology (Am J Physiol Renal Physiol) Vol. 317 Issue 2 Pg. F254-F263 (08 01 2019) ISSN: 1522-1466 [Electronic] United States
PMID31042060 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Cacna1g protein, mouse
  • Cacna1h protein, mouse
  • Calcium Channels, T-Type
  • Mineralocorticoid Receptor Antagonists
  • Receptors, Angiotensin
  • Angiotensin II
  • Aldosterone
  • Canrenoic Acid
  • Cytochrome P-450 CYP11B2
  • Renin
Topics
  • Adrenal Glands (enzymology)
  • Aldosterone (blood)
  • Angiotensin II
  • Animals
  • Arterial Pressure (drug effects)
  • Biomarkers (blood)
  • Calcium Channels, T-Type (deficiency, genetics)
  • Canrenoic Acid (pharmacology)
  • Cardiomegaly (blood, genetics, pathology)
  • Cytochrome P-450 CYP11B2 (metabolism)
  • Disease Models, Animal
  • Female
  • Fibrosis
  • Hypertension (blood, genetics, physiopathology, prevention & control)
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mineralocorticoid Receptor Antagonists (pharmacology)
  • Myocardium (metabolism, pathology)
  • Receptors, Angiotensin (metabolism)
  • Renin (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: